Expression profiles of CYP1A1 and CYP1B1 enzymes in Non-small Cell Lung Cancer of Turkish Patients
https://doi.org/10.21294/1814-4861-2025-24-1-39-48
Abstract
Background. The cytochrome P450 enzymes CYP1A1 and CYP1B1 are involved in the metabolism of carcinogens and have been linked to various cancers, including lung cancer, primarily through their overexpression in tumor tissues. Aim of study. This study describes the CYP1A1 and CYP1B1 expression profiles in lung adenocarcinoma (AC) and lung squamous cell carcinoma (SCC), and explores the possible associations with demographic and clinical features among Turkish patients. Material and methods. This retrospective study analyzed clinical data from 40 patients with lung adenocarcinoma and lung squamous cell carcinoma. tumor and adjacent healthy tissue samples were immunohistochemically stained to profile CYP1A1 and CYP1B1 expression. Associations between protein expression levels and patient characteristics were examined. Results. Significant immunohistochemical differences were found between tumorous and healthy tissues for CYP1A1 and CYP1B1. Conclusion. The study suggests that the CYP1A1 and CYP1B1 expression profiles in lung adenocarcinoma and lung squamous cell carcinoma among Turkish patients may have biomarker value for risk stratification and early detection.
About the Authors
H. Bayram
Department of Biology, Faculty of Arts and Sciences, Kirikkale University
Turkey
Turkey
Hakan Bayram - Biologist, Department of Biology, Faculty of Arts and Sciences, Central Research Laboratory, Kırıkkale University.
Kirikkale
O. Dirican
Department of Pathology Laboratory Techniques, Vocational School of Health Services, Istanbul Gelişim University
Turkey
Turkey
Onur Dirican - Assistant Professor, Senior scientist, Department of Pathology Laboratory Techniques, Vocational School of Health Services, Istanbul Gelisim University.
Istanbul
P. Kaygın
Department of Biology, Faculty of Arts and Sciences, Kirikkale University
Turkey
Turkey
Pınar Kaygin - MSc, Biologist, Department of Biology, Faculty of Arts and Sciences, Kırıkkale University.
Kirikkale
K. Başak
Department of Pathology, Kartal Dr. Lütfi Kırdar City Hospital, Turkish Ministry of Health, University of Health Sciences
Turkey
Turkey
Kayhan Başak - MD, Associate Professor, Department of Pathology, Kartal Dr. Lütfi Kırdar City Hospital, Turkish Ministry of Health, University of Health Sciences.
İstanbul
A. A. Husseini
Life Sciences and Biomedical Engineering Application and Research Centre, Istanbul Gelisim University
Turkey
Turkey
Abbas Ali Husseını - Assistent Professor, Senior scientist, Life Sciences and Biomedical Engineering Application and Research Centre, Istanbul Gelisim University.
Istanbul
M. Atlı
Department of Biology, Faculty of Arts and Sciences, Kirikkale University
Turkey
Turkey
Muharrem Atlı - MSc, PhD, Researcher, Department of Biology, Faculty of Arts and Sciences, Kırıkkale University.
Kirikkale
F. Ç. Kazancı
Medical Pathology Clinic, Çerkezkoy State Hospital
Turkey
Turkey
Fatma Çakmak Kazancı - MD, Clinician, Medical Pathology Clinic, Çerkezköy State Hospital.
İstanbul
S. Oğuztüzün
Department of Biology, Faculty of Arts and Sciences, Kirikkale University
Turkey
Turkey
Serpil Oğuztüzün - Professor Dr., Department of Biology, Faculty of Arts and Sciences, Kırıkkale University.
Kirikkale
References
1. Thandra K.C., Barsouk A., Saginala K., Aluru J.S., Barsouk A. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021; 25(1): 45–52. doi: 10.5114/wo.2021.103829.
2. WHO (2024). Global cancer burden growing, amidst mounting need for services [Internet]. [cited 2024 Aug 1]. URL: https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services.
3. NicholsonA.G., Tsao M.S., Beasley M.B., BorczukA.C., Brambilla E., Cooper W.A., Dacic S., Jain D., Kerr K.M., Lantuejoul S., Noguchi M., Papotti M., Rekhtman N., Scagliotti G., van Schil P., Sholl L., Yatabe Y., Yoshida A., Travis W.D. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol. 2022; 17(3): 362–87. doi: 10.1016/j.jtho.2021.11.003.
4. Zappa C., Mousa S.A. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016; 5(3): 288–300. doi: 10.21037/tlcr.2016.06.07.
5. Dougall A.L. Cancer: lung. Cambridge Handbook of Psychology, Health and Medicine. 2nd ed. Cambridge: Cambridge University Press, 2007. pp 605–606.
6. Kim J.H., Sherman M.E., Curriero F.C., Guengerich F.P., Strickland P.T., Sutter T.R. Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol Appl Pharmacol. 2004; 199(3): 210–9. doi: 10.1016/j.taap.2003.11.015.
7. San Jose C., Cabanillas A., Benitez J., Carrillo J.A., Jimenez M., Gervasini G. CYP1A1 gene polymorphisms increase lung cancer risk in a high-incidence region of Spain: a case control study. BMC Cancer. 2010; 10: 463. doi: 10.1186/1471-2407-10-463.
8. Androutsopoulos V.P., Tsatsakis A.M., Spandidos D.A. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer. 2009; 9. doi: 10.1186/1471-2407-9-187.
9. Tsay J.J., Tchou-Wong K.M., Greenberg A.K., Pass H., Rom W.N. Aryl hydrocarbon receptor and lung cancer. Anticancer Res. 2013; 33(4): 1247–56.
10. Smith G.B., Harper P.A., Wong J.M., Lam M.S., Reid K.R., Petsikas D., Massey T.E. Human lung microsomal cytochrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, aryl hydrocarbon receptor, and glutathione S-transferase M1 genetic polymorphisms. Cancer Epidemiol Biomarkers Prev. 2001; 10(8): 839–53.
11. Carrera A.N., Grant M.K.O., Zordoky B.N. CYP1B1 as a therapeutic target in cardio-oncology. Clin Sci (Lond). 2020; 134(21): 2897–927. doi: 10.1042/CS20200310.
12. Zhang S., Li D., Han X. Systematic evaluation of clinical efficacy of CYP1B1 gene polymorphism in EGFR mutant non-small cell lung cancer observed by medical image. Open Life Sci. 2023; 18(1). doi: 10.1515/biol-2022-0688.
13. Polat F., Buluş H., Kaygın P., Dirican O., Şimşek G.G., Sarıaltın S.Y., Gürbüz F.N., Yılmaz C., Oğuztüzün S. Investigation of the role of CYP1A1 and CYP1B1 expressions in obesity susceptibility. Türk Doğa ve Fen Dergisi. 2022; 11(3): 69–78. https://doi.org/10.46810/tdfd.1109600.
14. Su J.M., Lin P., Wang C.K., Chang H. Overexpression of cytochrome P450 1B1 in advanced non-small cell lung cancer: a potential therapeutic target. Anticancer Res. 2009; 29(2): 509–15.
15. Rodriguez M., Potter D.A. CYP1A1 regulates breast cancer proliferation and survival. Mol Cancer Res. 2013; 11(7): 780–92. doi: 10.1158/1541-7786.MCR-12-0675.
16. García-Martínez A., Gamboa-Loira B., Tejero M.E., Sierra-Santoyo A., Cebrián M.E., López-Carrillo L. CYP1A1, CYP1B1, GSTM1 and GSTT1 genetic variants and breast cancer risk in Mexican women. Salud Publica Mex. 2017; 59(5): 540–47. doi: 10.21149/8527.
17. Androutsopoulos V.P., Spyrou I., Ploumidis A., Papalampros A.E., Kyriakakis M., Delakas D., Spandidos D.A., Tsatsakis A.M. Expression profile of CYP1A1 and CYP1B1 enzymes in colon and bladder tumors. PLoS One. 2013; 8(12). doi: 10.1371/journal.pone.0082487.
18. Wenzlaff A.S., Cote M.L., Bock C.H., Land S.J., Santer S.K., Schwartz D.R., Schwartz A.G. CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis. 2005; 26(12): 2207–12. doi: 10.1093/carcin/bgi191.
Review
For citations:
Bayram H., Dirican O., Kaygın P., Başak K., Husseini A.A., Atlı M., Kazancı F.Ç., Oğuztüzün S. Expression profiles of CYP1A1 and CYP1B1 enzymes in Non-small Cell Lung Cancer of Turkish Patients. Siberian journal of oncology. 2025;24(1):39-48. https://doi.org/10.21294/1814-4861-2025-24-1-39-48
Views:
747
Email this article 
